Toxicology – Sodium Polystyrene Sulfonate (SPS)

Core Concept

Sodium polystyrene sulfonate (SPS; historically Kayexalate) is a nonabsorbed gastrointestinal cation-exchange resin that can increase fecal potassium elimination.

Historically, SPS was commonly used for hyperkalemia. Its modern role is much more limited because:

• Potassium removal is relatively slow.
• The magnitude and predictability of effect are limited.
• It does not rapidly stabilize life-threatening hyperkalemia.
• Important gastrointestinal complications can occur.

Therefore, SPS should not be relied upon as emergency monotherapy for severe hyperkalemia.

Mechanism of Action

SPS is a negatively charged polymer containing sodium.

Within the gastrointestinal tract, it exchanges sodium for other positively charged ions, particularly potassium:

SPS–Na + K⁺ → SPS–K + Na⁺

Potassium bound to the resin remains in the intestinal lumen and is subsequently eliminated in stool.

The result is:

↑ fecal potassium excretion → gradual reduction in total-body potassium

Site of Action

Cation exchange occurs throughout the gastrointestinal tract, with clinically relevant exchange occurring particularly in the colon.

The effect depends on:

• Gastrointestinal transit
• Amount of potassium available for exchange
• Duration of intestinal contact
• Resin exposure

Consequently, the response can be slow and variable.

SPS Does Not Rapidly Shift Potassium Into Cells

This distinction is essential.

SPS attempts to remove potassium from the body.

It does not rapidly redistribute extracellular potassium into cells.

By comparison:

• Insulin shifts potassium intracellularly.
• Beta₂-agonists can shift potassium intracellularly.
• Sodium bicarbonate may promote intracellular movement in selected acidemic patients.

These interventions act much faster than SPS.

SPS Does Not Stabilize the Myocardium

SPS also does not directly protect cardiac conduction from hyperkalemia.

When dangerous ECG abnormalities are present, IV calcium is used to stabilize the cardiac membrane.

Thus:

Calcium → cardiac stabilization

Insulin/glucose ± beta₂ agonist → temporary intracellular shift

Dialysis/GI binders/renal excretion → potassium removal

These interventions serve different purposes.

Hyperkalemia

Hyperkalemia can cause life-threatening cardiac conduction disturbances.

Possible ECG abnormalities include:

• Peaked T waves
• PR prolongation
• P-wave flattening or disappearance
• QRS widening
• Bradyarrhythmias
• Sine-wave morphology
• Ventricular fibrillation
• Asystole

However, ECG findings are not perfectly sensitive.

A relatively normal ECG does not exclude dangerous hyperkalemia.

Modern Management of Severe Hyperkalemia

Treatment is organized around three goals:

1. Stabilize the heart

IV calcium when clinically indicated.

2. Temporarily shift potassium intracellularly

Common strategies include:

• Insulin with appropriate glucose management
• Nebulized beta₂-agonist
• Bicarbonate in selected patients, particularly when significant metabolic acidosis is contributing

3. Remove potassium from the body

Options include:

• Renal potassium excretion when kidney function permits
• Gastrointestinal potassium binders in selected circumstances
• Hemodialysis, particularly for severe or refractory hyperkalemia and significant renal failure

SPS belongs only to the third category and acts relatively slowly.

SPS in Life-Threatening Hyperkalemia

The older source describes SPS as an adjunct in life-threatening hyperkalemia.

Modern practice places substantially less emphasis on it.

In a patient with:

• Major ECG abnormalities
• Severe weakness or paralysis
• Rapidly rising potassium
• Significant renal failure
• Refractory hyperkalemia

SPS should never delay established emergency therapy or dialysis.

Evidence for Effectiveness

SPS can lower potassium, but its acute effect is:

• Delayed
• Variable
• Difficult to predict

Evidence supporting its usefulness for immediate emergency potassium reduction is considerably weaker than historical practice suggested.

Therefore, it is better regarded as a possible nonemergent adjunct in carefully selected patients rather than a rescue antidote.

Sorbitol – Important Safety Issue

Historically, SPS was frequently administered with sorbitol to prevent constipation and accelerate intestinal transit.

This combination became associated with serious gastrointestinal injury, including:

• Ischemic colitis
• Ulceration
• Gastrointestinal bleeding
• Intestinal necrosis
• Perforation

High-concentration sorbitol formulations are therefore particularly problematic.

Intestinal Necrosis

Although uncommon, intestinal necrosis is the most concerning adverse effect associated with SPS.

Risk may be greater in patients with:

• Postoperative bowel dysfunction
• Ileus
• Constipation or impaired intestinal motility
• Bowel ischemia
• Severe systemic illness
• Renal failure
• Other conditions compromising intestinal perfusion

SPS should be avoided when gastrointestinal transit or bowel integrity is substantially impaired.

Other Gastrointestinal Effects

More common adverse effects include:

• Nausea
• Vomiting
• Constipation
• Diarrhea
• Abdominal discomfort
• Fecal impaction

Severe abdominal pain, distension, gastrointestinal bleeding, or peritoneal findings after SPS require urgent evaluation for intestinal injury.

Sodium Load

SPS exchanges sodium for potassium.

Therefore, repeated treatment can increase sodium exposure.

Potential consequences include:

• Sodium retention
• Edema
• Hypertension
• Fluid overload

Particular caution is appropriate in:

• Heart failure
• Advanced kidney disease
• Severe hypertension
• Other sodium-sensitive states

Electrolyte Disturbances

SPS is not perfectly selective for potassium.

It can also bind other cations.

Potential abnormalities include:

• Hypokalemia
• Hypomagnesemia
• Hypocalcemia

Serial electrolyte monitoring is therefore important when repeated treatment is used.

Hypokalemia

Excess potassium removal can produce clinically important hypokalemia.

Possible manifestations include:

• Weakness
• Muscle cramps
• Ileus
• ECG abnormalities
• Dysrhythmias

Treatment should therefore be reassessed as potassium normalizes.

Drug Binding and Interactions

SPS can bind medications within the gastrointestinal tract and reduce their absorption.

This interaction is broader than the older source’s emphasis on antacids and laxatives.

Therefore, other oral medications generally require appropriate separation from SPS according to current product guidance, with particular caution for drugs with a narrow therapeutic index.

Magnesium-Containing Products

Combining SPS with certain magnesium-containing antacids or laxatives can cause clinically important electrolyte or acid–base abnormalities.

Unnecessary simultaneous use should be avoided.

Lithium Poisoning

Because SPS exchanges cations, it can bind lithium in the gastrointestinal tract.

Older volunteer studies suggested that SPS could:

• Reduce lithium absorption
• Increase gastrointestinal lithium elimination

However, this has not translated into an established clinical role in lithium poisoning.

Why SPS Is Not Standard Therapy for Lithium Toxicity

Serious lithium poisoning may involve:

• Neurologic toxicity
• Tremor
• Ataxia
• Confusion
• Myoclonus
• Seizures
• Coma
• Renal impairment

The most important measures are:

• Stop lithium exposure
• Appropriate isotonic fluid therapy when indicated
• Serial lithium concentrations
• Renal and electrolyte monitoring
• Hemodialysis for selected severe toxicity

SPS should not delay dialysis.

Lithium Already Absorbed Into the Body

Binding lithium within the intestine does not reliably address lithium that has already entered:

• Plasma
• Brain
• Other tissues

This is particularly important in chronic lithium toxicity, where neurologic toxicity can be severe despite concentrations that might not appear dramatically elevated.

Newer Potassium Binders

Other gastrointestinal potassium-binding agents are now available, including:

• Patiromer
• Sodium zirconium cyclosilicate

They differ from SPS in:

• Binding characteristics
• Onset
• Adverse-effect profile
• Sodium exposure
• Drug interactions

Their existence has further reduced reliance on SPS for many nonemergency situations.

Potassium Binders Are Not Interchangeable

Each potassium binder has its own:

• Indications
• Contraindications
• Onset of effect
• Interaction profile

None should automatically replace immediate cardiac stabilization and intracellular potassium shifting when a patient has dangerous acute hyperkalemia.

Hemodialysis

Dialysis directly removes potassium from the bloodstream and is particularly important when severe hyperkalemia occurs with:

• Significant renal failure
• Refractory potassium elevation
• Ongoing potassium release
• Severe ECG toxicity
• Failure of temporizing therapies

In such circumstances, repeated SPS administration is not an adequate substitute.

Pregnancy and Lactation

The historical FDA Category C designation is obsolete.

SPS itself is minimally systemically absorbed, but its:

• Gastrointestinal effects
• Sodium load
• Electrolyte consequences

remain clinically relevant.

Use during pregnancy or lactation should therefore be based on the clinical need and availability of more appropriate alternatives rather than an obsolete letter category.

Contraindications and Major Precautions

SPS should generally be avoided or used with particular caution in patients with:

• Existing hypokalemia
• Significant bowel obstruction
• Ileus
• Markedly impaired gastrointestinal motility
• Suspected bowel ischemia
• High risk for intestinal necrosis
• Previous serious hypersensitivity

Sodium-sensitive conditions also require caution.

Monitoring

When SPS is used, monitor:

• Serum potassium
• Sodium
• Magnesium
• Calcium
• Renal function
• Fluid status
• Gastrointestinal function

For severe hyperkalemia, also monitor:

• Continuous ECG when appropriate
• Glucose after insulin therapy
• Serial potassium concentrations

Do Not Wait for SPS to Work

In acute dangerous hyperkalemia:

SPS is too slow and unpredictable to be the principal emergency intervention.

The immediate priorities are:

Cardiac stabilization → intracellular potassium shift → definitive potassium removal

Important Modernization of the Older Source

• SPS is a gastrointestinal cation-exchange resin that increases fecal potassium loss.
• It exchanges sodium for potassium and other cations.
• Its potassium-lowering effect is relatively slow and variable.
• SPS should not be relied upon as emergency monotherapy for life-threatening hyperkalemia.
• IV calcium stabilizes the myocardium but does not lower serum potassium.
• Insulin and beta₂-agonists temporarily shift potassium intracellularly but do not remove it from the body.
• Dialysis provides rapid definitive potassium removal in selected severe cases.
• Routine use of SPS in acute severe hyperkalemia has declined substantially.
• SPS can cause constipation, impaction, intestinal ischemia, necrosis, and rarely perforation.
• Historical SPS–sorbitol combinations are particularly associated with gastrointestinal injury.
• Sodium loading can worsen edema, hypertension, and heart failure.
• SPS may cause hypokalemia, hypomagnesemia, and hypocalcemia.
• SPS can bind other oral medications and interfere with absorption.
• Although SPS can bind lithium experimentally, it has no established routine role in lithium poisoning.
• Hemodialysis remains the major extracorporeal treatment for selected severe lithium toxicity.
• Patiromer and sodium zirconium cyclosilicate provide newer gastrointestinal potassium-binding options, although their roles and onset differ.
• Historical FDA pregnancy categories are obsolete.
• Exact SPS dosing should follow current product and institutional guidance rather than historical emergency regimens.

Key Points

• SPS–Na + K⁺ → SPS–K → fecal potassium elimination.
• SPS removes potassium but does not rapidly shift it into cells or stabilize the myocardium.
• Its onset is too slow and unpredictable to make it the primary treatment for dangerous acute hyperkalemia.
• Calcium protects the heart; insulin/beta₂-agonists shift potassium; dialysis removes potassium definitively in selected severe cases.
• Serious gastrointestinal injury, including intestinal necrosis, is the major safety concern.
• Sorbitol-containing preparations have particular historical safety concerns.
• Repeated SPS can cause sodium overload and depletion of potassium, magnesium, and calcium.
• Its proposed lithium-binding effect has not established SPS as a routine treatment for lithium poisoning.
• In severe hyperkalemia, never allow administration of a gastrointestinal potassium binder to delay immediate cardiac stabilization or definitive therapy.